SCHEMBL16397403

SCHEMBL16397403

CC(=O)Nc1cc(Br)cc(C(=O)O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 2/20 0.53
CREBBP Q92793 1/20 0.50
LMNA P02545 2/20 0.47
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
PKM P14618 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
NTSR1 P30989 1/20 0.41
ATM Q13315 1/20 0.41
GAA P10253 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
CSNK2A3 Q8NEV1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2735596 0.86 MEN1 (0.56) MEN1KMT2APOLBLMNAL3MBTL1
SCHEMBL618917 0.86 L3MBTL1 (0.57) MEN1KMT2APOLBLMNARAB9A
SCHEMBL22864579 0.84 LMNA (0.58) MEN1KMT2ALMNARAB9AL3MBTL1
SCHEMBL16397173 0.82 GAA (0.58) MEN1KMT2APOLBCREBBPRAB9A
SCHEMBL28566356 0.81 POLB (0.43) MEN1KMT2APOLBLMNARAB9A
SCHEMBL10148977 0.79 TPMT (0.59) MEN1KMT2APOLBLMNAL3MBTL1
SCHEMBL11936746 0.79 CREBBP (0.52) MEN1KMT2APOLBCREBBPLMNA
SCHEMBL29152083 0.78 LMNA (0.47) MEN1KMT2APOLBLMNARAB9A
SCHEMBL21855109 0.78 L3MBTL1 (0.53) MEN1KMT2APOLBLMNAL3MBTL1
SCHEMBL5108982 0.78 ALDH1A1 (0.53) MEN1KMT2APOLBLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB MEN1 689/4885KMT2A 1918/4885POLB 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.